Log in or Sign up for Free to view tailored content for your specialty!
Pulmonary Vascular Disease News
96% of patients with PAH prefer a single-tablet combination therapy
When presented with four unlabeled treatment profiles showing five treatment attributes, 96% of patients with pulmonary arterial hypertension chose a single-tablet vs. a multi-tablet combination therapy, according to a poster.
Q&A: Yutrepia for PAH, pulmonary hypertension-ILD receives tentative FDA approval
Around 7 months after not meeting the Prescription Drug User Fee Act goal date for Yutrepia, the FDA has tentatively approved the drug for pulmonary arterial hypertension and pulmonary hypertension-associated interstitial lung disease.
FDA designates recall of catheter for large blood vessel clot removal as class I
Inari Medical has issued a recall and update to the instructions for use of its 30 mm thrombectomy catheter due to risk for injury and death from device entrapment and pulmonary emboli.
Log in or Sign up for Free to view tailored content for your specialty!
AI models detect pulmonary embolism early with medical record data
Two machine learning-based models using only medical record data had high accuracy in detecting individuals with and without pulmonary embolism at hospital admission, according to results published in Journal of Medical Internet Research.
Clinicians agree on individualized dosing, titration of selexipag in PAH
Health care professionals treating patients with pulmonary arterial hypertension recommend individualized dosing and titration of oral selexipag, according to a poster presented at the International Pulmonary Hypertension Conference.
FDA grants orphan drug designation to PAH treatment
The FDA granted orphan drug designation to ZMA001 as a treatment for patients with pulmonary arterial hypertension, according to a press release from Zymedi.
CPAP lowers vascular inflammation, unstable plaque volume in OSA
Adults with obstructive sleep apnea treated with CPAP for 24 weeks had improved vascular inflammation and lower unstable plaque volume, according to results published in Annals of the American Thoracic Society.
Electrocardiogram-based AI algorithm identifies pulmonary hypertension before diagnosis
An AI algorithm had high discriminative ability in identifying pulmonary hypertension-likely patients from control patients at and before diagnosis using electrocardiogram data, according to study results.
Inhaled seralutinib reduces vascular resistance in patients with PAH over 72 weeks
SAN DIEGO — Among patients with pulmonary arterial hypertension, seralutinib lowered pulmonary vascular resistance over 72 weeks, according to research presented at the American Thoracic Society International Conference.
Combination macitentan, tadalafil tablet improves exercise capacity in PAH
SAN DIEGO — Exercise capacity improved among adults with pulmonary arterial hypertension taking a macitentan-tadalafil tablet over 68 weeks, according to research presented at the American Thoracic Society International Conference.
-
Headline News
‘The mind is medicine’: How virtual reality can cool bothersome hot flashes
September 18, 20244 min read -
Headline News
CDC: Close contact of Missouri bird flu case had symptoms but was not tested
September 17, 20242 min read -
Headline News
Metformin use may lower risk for long COVID in adults with type 2 diabetes
September 18, 20243 min read
-
Headline News
‘The mind is medicine’: How virtual reality can cool bothersome hot flashes
September 18, 20244 min read -
Headline News
CDC: Close contact of Missouri bird flu case had symptoms but was not tested
September 17, 20242 min read -
Headline News
Metformin use may lower risk for long COVID in adults with type 2 diabetes
September 18, 20243 min read